scholarly journals DIRECT-ACTING ANTIVIRALS DURING OR AFTER IMMUNO-CHEMOTHERAPY IN HEPATITIS C VIRUS-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMAS

2017 ◽  
Vol 35 ◽  
pp. 194-196
Author(s):  
M. Merli ◽  
L. Alric ◽  
L. Mannelli ◽  
F. De Angelis ◽  
A. Ferrari ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
B Cell ◽  
Direct Acting Antivirals ◽  
B Cell Lymphomas ◽  
Direct Acting ◽  
Large B Cell

scholarly journals Direct‐Acting Antivirals in Hepatitis C Virus‐Associated Diffuse Large B‐cell Lymphomas

2018 ◽  
Vol 24 (8) ◽  
Author(s):  
Michele Merli ◽  
Marco Frigeni ◽  
Laurent Alric ◽  
Carlo Visco ◽  
Caroline Besson ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
B Cell ◽  
Direct Acting Antivirals ◽  
B Cell Lymphomas ◽  
Direct Acting ◽  
Large B Cell

Direct-acting antivirals during or after immunochemotherapy in hepatitis C virus-positive diffuse large B-cell lymphomas

Hepatology ◽  
2017 ◽  
Vol 66 (4) ◽  
pp. 1341-1343 ◽  
Author(s):  
Michele Merli ◽  
Marco Frigeni ◽  
Manuel Gotti ◽  
Paolo Grossi ◽  
Raffaele Bruno ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
B Cell ◽  
Direct Acting Antivirals ◽  
B Cell Lymphomas ◽  
Direct Acting ◽  
Large B Cell

scholarly journals Concomitant Treatment of Hepatitis C Virus and Diffuse Large B-Cell Lymphoma with Direct-Acting Antivirals in HIV Coinfection: A Case Report

2019 ◽  
Vol 18 ◽  
pp. 232595821882206
Author(s):  
Alyssa Gallipani ◽  
Agnes Cha ◽  
Leonard Berkowitz ◽  
Anjali Bakshi
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Concomitant Treatment ◽  
Direct Acting Antivirals ◽  
Large B Cell Lymphoma ◽  
Direct Acting ◽  
Large B Cell

This report describes a case of concomitant treatment of advanced diffuse large B-cell lymphoma with chemoimmunotherapy along with direct-acting antivirals for hepatitis C virus in a patient coinfected with HIV. The patient tolerated gemcitabine, dexamethasone, cisplatin, and rituximab and achieved sustained virologic response after treatment with ledipasvir/sofosbuvir.

Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma

2020 ◽  
Vol 61 (9) ◽  
pp. 2122-2128 ◽  
Author(s):  
Michele Merli ◽  
Irene Defrancesco ◽  
Carlo Visco ◽  
Caroline Besson ◽  
Alice Di Rocco ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Direct Acting Antivirals ◽  
Large B Cell Lymphoma ◽  
Direct Acting ◽  
Large B Cell

scholarly journals Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations

2017 ◽  
Vol 117 (11) ◽  
pp. 1685-1688 ◽  
Author(s):  
Carlo Visco ◽  
Jinfen Wang ◽  
Maria Chiara Tisi ◽  
Lijuan Deng ◽  
Emanuele S G D'Amore ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
B Cell ◽  
B Cell Lymphomas ◽  
Molecular Features ◽  
Large B Cell

scholarly journals Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Machiko Umemura ◽  
Goki Suda ◽  
Shihori Tsukamoto ◽  
Ko Ebata ◽  
Shinjiro Takahash ◽  
...  
Keyword(s):  
Hepatitis C ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Direct Acting Antivirals ◽  
On Demand ◽  
Large B Cell Lymphoma ◽  
First Case ◽  
Direct Acting ◽  
Large B Cell

Abstract Background In patients with hepatitis C virus (HCV) and malignant lymphoma, hepatitis C flare during R-CHOP can result in discontinuation of treatment. However, appropriate therapeutic strategies for managing hepatitis C flare during R-CHOP have not been established, and this issue is complicated by conflicting results regarding the use of direct-acting antivirals in patients with uncontrolled malignancies. Case presentation We report the first case of effective and safe treatment with on-demand 8-week glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in a patient with diffuse large B-cell lymphoma (DLBCL). The patient completed five additional courses of R-CHOP without hepatic toxicity. A complete response of DLBCL and a sustained virological response were observed at 24 weeks after glecaprevir and pibrentasvir completion. Conclusion On-demand, direct-acting antivirals could be a novel strategy for managing hepatitis C flare during R-CHOP.

Sign in / Sign up

Export Citation Format

Share Document